These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Current colorectal cancer screening strategies: overview and obstacles to implementation. Rex DK Rev Gastroenterol Disord; 2002; 2 Suppl 1():S2-11. PubMed ID: 12439393 [TBL] [Abstract][Full Text] [Related]
10. [Colorectal exfoliated cell in stool and its nuclear DNA quantitative analysis for diagnosis of colorectal cancer]. Fan RY; Li SR; Wu ZT; Wu X; Chen ZM Ai Zheng; 2002 Jul; 21(7):776-80. PubMed ID: 12479106 [TBL] [Abstract][Full Text] [Related]
11. Stool test for colorectal cancer screening--it's time to move! Loitsch SM; Shastri Y; Stein J Clin Lab; 2008; 54(11-12):473-84. PubMed ID: 19216253 [TBL] [Abstract][Full Text] [Related]
12. Improved fecal DNA test for colorectal cancer screening. Itzkowitz SH; Jandorf L; Brand R; Rabeneck L; Schroy PC; Sontag S; Johnson D; Skoletsky J; Durkee K; Markowitz S; Shuber A Clin Gastroenterol Hepatol; 2007 Jan; 5(1):111-7. PubMed ID: 17161655 [TBL] [Abstract][Full Text] [Related]
13. Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. Berger BM; Ahlquist DA Pathology; 2012 Feb; 44(2):80-8. PubMed ID: 22198259 [TBL] [Abstract][Full Text] [Related]
14. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594 [TBL] [Abstract][Full Text] [Related]
15. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data]. Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127 [TBL] [Abstract][Full Text] [Related]
16. Stool test for colorectal cancer screening: what is going on? Bonanno E; Rulli F; Galatà G; Pucci S; Sesti F; Farinon AM; Spagnoli LG Surg Oncol; 2007 Dec; 16 Suppl 1():S43-5. PubMed ID: 18055195 [TBL] [Abstract][Full Text] [Related]
17. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Loktionov A; O'Neill IK; Silvester KR; Cummings JH; Middleton SJ; Miller R Clin Cancer Res; 1998 Feb; 4(2):337-42. PubMed ID: 9516920 [TBL] [Abstract][Full Text] [Related]
18. Colorectal cancer screening using stool DNA analysis in clinical practice: early clinical experience with respect to patient acceptance and colonoscopic follow-up of abnormal tests. Berger BM; Schroy PC; Rosenberg JL; Lai-Goldman M; Eisenberg M; Brown T; Rochelle RB; Billings PR Clin Colorectal Cancer; 2006 Jan; 5(5):338-43. PubMed ID: 16512992 [TBL] [Abstract][Full Text] [Related]
19. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Graser A; Stieber P; Nagel D; Schäfer C; Horst D; Becker CR; Nikolaou K; Lottes A; Geisbüsch S; Kramer H; Wagner AC; Diepolder H; Schirra J; Roth HJ; Seidel D; Göke B; Reiser MF; Kolligs FT Gut; 2009 Feb; 58(2):241-8. PubMed ID: 18852257 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. Tsoi KK; Ng SS; Leung MC; Sung JJ Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]